Trapani Dario, Nidhamalddin Sara J, Gandini Sara, Filetti Marco, Altuna Sara C, Carnevale Schianca Ambra, Petrillo Angelica, Murthy Shilpa M, Girardi Fabio, Bezuidenhout Jacques B, El Bairi Khalid, Lombardi Pasquale, Khan Shah Z, Lengyel Csongor G, Seeber Andreas, Hussain Sadaqat, Seid Fahmi U, Elfaham Essam, Odhiambo Andrew O, Coskun Yakup, Baker Habeeb S, Chowdhury Arman R, Genazzani Armando, Daniele Gennaro, Porzio Giampiero, Curigliano Giuseppe, Giusti Raffaele
European Institute of Oncology, IRCCS, Milan, Italy; University of Milan, Department of Oncology and Hematology, Milan, Italy.
Medical Oncologist, Hiwa Cancer Hospital, Iraq.
Eur J Cancer. 2025 Jan 17;215:115158. doi: 10.1016/j.ejca.2024.115158. Epub 2024 Nov 30.
Medical cannabis (MC) has gained traction in oncology for managing cancer-related symptoms, but its integration faces challenges due to limited evidence, inconsistent guidelines, and varied legal frameworks.
The TASMAN study aimed to assess the knowledge, attitudes, and practices of oncologists and palliative care providers globally regarding MC use in cancer care. A survey of healthcare providers from diverse regions and income levels was conducted.
we study included 179 participants (response rate: 51.1 %), with an equal gender distribution (49.4 % female) and a median age of 37 years. Participants were primarily oncologists (71.5 %), practicing in university hospitals (40.2 %) or cancer centres (32.4 %), with over half from low- and middle-income countries. Most respondents (92.7 %) were unaware of clinical guidelines for MC. A proportion of 44.1 % were familiar with MC use, 78.8 % recognized its role in cancer pain, and 34 % identified its role in managing cachexia. Awareness of specific products was low, with only 10 % familiar with specific cannabis products. Three-quarters of respondents (84.4 %) did not prescribe MC routinely. Legal status and regulations were unclear for most participants; 40 % noted cannabis as illegal. MC use and patient requests were more common in high-income countries and the EURO region, with palliative care providers demonstrating the highest awareness and prescription rates.
Clearer regulations, standardized guidelines, and targeted education are essential to support the safe integration of MC into oncology and palliative care, ultimately improving the quality of life for cancer patients.
医用大麻在肿瘤学领域因用于管理癌症相关症状而受到关注，但其整合面临挑战，原因包括证据有限、指南不一致以及法律框架各异。
塔斯曼研究旨在评估全球肿瘤学家和姑息治疗提供者在癌症治疗中使用医用大麻的知识、态度和实践。对来自不同地区和收入水平的医疗保健提供者进行了一项调查。
我们的研究纳入了179名参与者（回复率：51.1%），性别分布均衡（女性占49.4%），中位年龄为37岁。参与者主要是肿瘤学家（71.5%），在大学医院（40.2%）或癌症中心（32.4%）执业，超过一半来自低收入和中等收入国家。大多数受访者（92.7%）不了解医用大麻的临床指南。44.1%的人熟悉医用大麻的使用，78.8%的人认识到其在癌症疼痛中的作用，34%的人确定其在管理恶病质中的作用。对特定产品的知晓度较低，只有10%的人熟悉特定的大麻产品。四分之三的受访者（84.4%）没有常规开具医用大麻处方。对大多数参与者来说，法律地位和法规不明确；40%的人指出大麻是非法的。医用大麻的使用和患者请求在高收入国家和欧洲地区更为常见，姑息治疗提供者的知晓度和处方率最高。
更明确的法规、标准化指南和有针对性的教育对于支持医用大麻安全融入肿瘤学和姑息治疗至关重要，最终可改善癌症患者的生活质量。
